SBI Securities’s Pacira BioSciences PCRX Stock Holding History

SBI Securities’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$254	Hold	10	–	–	﹤0.01%	3254
2026 Q1	$226	Hold	10	–	–	﹤0.01%	3176
2025 Q4	$259	Sell	10 -2	-17%	-$48	﹤0.01%	3129
2025 Q3	$309	Sell	12 -14	-54%	-$344	﹤0.01%	3173
2025 Q2	$621	Hold	26	–	–	﹤0.01%	2876
2025 Q1	$646	Hold	26	–	–	﹤0.01%	2767
2024 Q4	$490	Buy	+26	New	+$456	﹤0.01%	2895

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SBI Securities's PCRX Position: Q2 2026 in Review

SBI Securities held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 10 shares worth $254. The position accounts for ﹤0.01% of the portfolio, ranked #3254.

SBI Securities first reported a position in PCRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $646 in Q1 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

SBI Securities held 10 shares of Pacira BioSciences worth $254 as of Q2 2026.
SBI Securities left its Pacira BioSciences share count unchanged in Q2 2026.
Pacira BioSciences made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3254 holding.
SBI Securities first reported a position in Pacira BioSciences in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Pacira BioSciences position peaked at $646 in Q1 2025.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.